Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2015—The Clinical and Laboratory Standards Institute published a new document titled “Laboratory Personnel Management (QMS16-Ed1).” This guideline describes the process for meeting the regulatory and accreditation requirements of personnel management in the laboratory environment.
December 2015—Oxford Gene Technology has entered into a deal with Baylor Miraca Genetics Laboratories, licensing the use of OGT’s proprietary single nucleotide polymorphism array probe technology.
December 2015—Luminex and Bio-Techne have signed a new distribution and supply agreement through 2020.
December 2015—BioTheranostics announced a collaboration agreement with Celsee Diagnostics (formerly DeNovo Sciences) to investigate the technical feasibility of using BioTheranostics’ proprietary biomarkers in the development of blood-based diagnostics.
December 2015—Thermo Scientific’s DRI Hydrocodone Assay received FDA 510(k) clearance; it also has the requisite sensitivities to meet the newly proposed Substance Abuse and Mental Health Services Administration guidelines (using a 300 ng/mL cutoff). SAMHSA oversees the testing of federally regulated employees, and many organizations follow the guidelines set forth by this agency.
December 2015—Diagnostica Stago launched its next-generation ecarin-based chromogenic assay for dabigatran, STA-ECA II. Fully automated with barcoded loading on Stago’s high throughput analyzers, STA-ECA II enables laboratories to measure dabigatran (Pradaxa) in plasma samples and is insensitive to lupus anticoagulants and heparin along with coagulation factor and fibrinogen levels.
November 2015—Quest Diagnostics announced that its Focus Diagnostics products business has received 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 and 2 Direct molecular test on the 3M Integrated Cycler.
November 2015—MDxHealth announced the commercial launch of its noninvasive, urine-based test, SelectMDx for prostate cancer, in Europe via the company’s laboratory facilities in Nijmegen, the Netherlands.
November 2015—Sarstedt introduced Lumox x-well cell culture chambers with a 50 µm ultrathin, gas-permeable film base that combines excellent imaging with superior cell growth. Compared with plastic or glass bases, the gas-permeable Lumox film provides more effective gas exchange and homogeneous cell growth.
November 2015—Affymetrix and Luminex announced a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex’s Magpix, Luminex 200, and Flexmap 3D multiplexed assay platforms in specified countries in the Americas, Asia, and Europe.
